Skip to content
InMed-logo-01
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

In the Media

  • June 29, 2022

The Intersection Between Medical and Health & Wellness: Force For Knowledge Cannabis Symposium Panel Discussion

InMed Pharmaceuticals’ Dr. Shane Johnson and Radicle Science’s Dr. Jeff Chen join the Force Family Office’s Force For Knowledge Cannabis Symposium: The Intersection Between Medical and Health & Wellness to talk about the importance of evidence-based research of cannabinoids. They discuss the need to provide medical professionals and consumers data and research-supported information to enable informed decision making.

They discuss the increasing interest in the physiological effects of rare cannabinoids and how recent research is unveiling the potential benefits. Radicle Science is conducting a large scale study, “Radicle Energy rare cannabinoid study”, on the effects of THCV on energy, focus/attention, appetite and weight/BMI.

Panel 3: The Intersection Between Medical and Health & Wellness
A discussion of the opportunities in pharmaceutical industry in addition to current health & wellness uses.

  • Shane Johnson, SVP, BayMedica a Division of InMed Pharmaceuticals
  • Jeff Chen, MD & MBA, CEO & Co-founder, Radicle Science
  • Mitch Baruchowitz, Founder & Managing Partner, Merida Capital Holdings

Event website: https://forcefamilyoffice.com/events/technology/force-for-knowledge-cannabis-symposium-panel-3-view-on-demand/

Panel discussion here: https://vimeo.com/725509153

 

Full Article
Source: Force Family Office

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Latest Articles

The Dales Report – InMed Pharmaceuticals Unveils Industry Leading Portfolio

Jerry P. Griffin, VP of Sales and Marketing at BayMedica, InMed’s subsidiary, is interviewed by Shadd Dales of the The Dales Report to talk about

Read More
July 5, 2022

Pharma Tech Outlook: InMed Introduces THCV Into the Health and Wellness Industry

InMed’s THCV will bring ample opportunity to the health sector to scale up in the market. Read full story via Pharma Tech Outlook.

Read More
July 4, 2022

What are cannabinoid analogs?

Cannabinoid analogs are novel cannabinoid compounds that are slightly modified from the naturally occurring cannabinoids in the plant. Since they have a new molecular structure

Read More
July 3, 2022
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Cannabinoid Analogs
  • Cannabinoids in Development

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

  • Cannabidivarin (CBDV)
  • Tetrahydrocannabivarin (THCV)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent